Why Amgen Inc. (AMGN) stock moved
Amgen Inc. (AMGN) shares rose 1.5% to $385.65 as of September 20, 2026, a modest gain from the prior close of $379.78. BestStocks flagged the session as a major change for AMGN. Below, we break down what changed for AMGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
AMGN climbed 1.5% to $385.65
AMGN rose 1.5% in its latest session, moving from $379.78 to $385.65.
What it means for Amgen Inc. investors
For Amgen Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 1.5% session move. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Because the move outpaced peers, it looks driven by AMGN-specific developments rather than a broad sector rotation. Wall Street's consensus price target sits at $393.72, implying +2.1% upside from $385.65. Over the past 90 days analysts logged 0 upgrades and 2 downgrades. BestStocks rates the overall signal quality medium (68/100). With earnings roughly 44 days out, the next report is the most likely near-term test of the move.
AMGN price reaction
AMGN last traded at $385.65, up $5.87 (+1.55%) from the previous close of $379.78. The session traded on 3.1× average volume (extreme), so the move carried above-average conviction. Its healthcare peer group moved a median -0.1% over the same stretch, leaving AMGN ahead of the group by 1.6 points. Over the past month the stock has ranged between $375.65 and $444.12, and it currently sits about 15% of the way up that band.
Bullish and bearish analyst opinions on Amgen Inc. (AMGN)
The consensus analyst price target on Amgen Inc. (AMGN) is $393.72, 2.1% above the recent $385.65. Over the past 90 days analysts logged 0 upgrades, 31 maintains, and 2 downgrades. Here is how the bullish and bearish cases on AMGN line up.
The bullish case
- Wall Street's consensus price target of $393.72 implies +2.1% upside from $385.65.
- The Street's most bullish target is $460.00 (+19.3%).
- Material positive event.
- Positive 1.5% session move.
- Volume 3.1x average — institutional conviction.
The bearish case
- The most bearish analyst target is $230.00 (-40.4%).
- 2 analyst downgrades in the past 90 days, most recently HSBC to Hold (2026-09-10).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for AMGN
Frequently asked questions about AMGN
Why did Amgen Inc. (AMGN) stock move?
AMGN rose 1.5% to $385.65. No single company-specific catalyst was confirmed during the move window, and it looks like a company-specific move.
How much did AMGN stock rise?
AMGN gained 1.55% ($5.87) versus the prior close of $379.78, last trading at $385.65 on 3.1× average volume.
When is Amgen Inc.'s next earnings date?
AMGN's next earnings report is estimated for 2026-11-03 — about 44 days away.
What is the analyst price target for AMGN?
The consensus analyst price target for AMGN is $393.72, about 2.1% above the current $385.65. Over the past 90 days, analysts recorded 0 upgrades, 31 maintains, and 2 downgrades.
Is the AMGN move company-specific or sector-wide?
BestStocks classifies it as a company-specific move: the peer group moved a median -0.1% against AMGN's +1.5%. AMGN ranks top 1 of 7 peers.
How BestStocks tracks AMGN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared AMGN-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for AMGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
